2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Study Population, Human, Adult, Elderly
PAPER

102 ASXL1 mutations disrupt genomic imprinting to activate DLK1-dependent stemness programs in chronic myelomonocytic leukemia (CMML)

Pankaj Pradeep, Terra Lasho, PhD2, Jenna Fernandez, Ph.D.3, Julia Castro Weiss4, Christy Finke, BS5, Nickolas Steinauer, M.D., Ph.D.6, Abhishek Avinash Mangaonkar, MBBS7, Kaaren Reichard, MD8, Aref Al-Kali, M.D.9, Clifford Csizmar, M.D., Ph.D.10, Martin Fernandez-Zapico, MD11, Eric Padron, MD12, Meher Gayatri Bolisetti, PhD13, Jing Zhang, MD14, Huihuang Yan, PhD15, Moritz Binder, MD, MPH16, Mrinal M. Patnaik, MD, MBBS17
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 University of Wisconsin Madison, Madison, Wisconsin, United States
14 University of Wisconsin Madison, Madison, Wisconsin, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States

Introduction: ASXL1 protein-truncating mutations occur in approximately 40% of chronic myelomonocytic leukemia (CMML) patients and are associated with inferior survival and resistance to epigenetic therapies. However, the epigenetic mechanisms linking ASXL1 mutations to stem-cell self-renewal and leukemogenesis remain poorly understood. Through integrated multiomic analyses, we investigated whether ASXL1 mutations alter enhancer activity and genomic imprinting to activate stemness-associated transcriptional programs.

Methods: We performed integrated multiomic profiling on bone marrow samples from 40 patients with CMML (19 ASXL1mt, 21 ASXL1-wildtype (wt)), median age 74 years, 80% male, including whole genome sequencing (WGS), bulk RNA-seq, DNA methylation profiling, ChIP-seq (H3K4me1, H3K27ac, H3K27me3 and H2BK20ac), single-cell RNA-seq, single-cell chromatin accessibility (GoTChA-seq) and Hi-C chromatin interaction analysis. A subset of these patients (5 ASXL1mt, 5 ASXL1wt) also underwent WGS and Biomodal duet evoC 6-base sequencing to profile genome-wide methylation (5mC) and hydroxymethylation (5hmC).

Differential enhancer accessibility was integrated with ENCODE annotations to identify ASXL1 mutation-specific regulatory elements. For haplotype phasing, the WGS data underwent stringent heterozygous SNP filtering through DeepVariant (v1.10.0) to generate heterozygous VCFs. Statistical phasing via Beagle (v5.5), anchored to the 1000 Genomes Project high-coverage haplotype reference, assigned every heterozygous SNP to haplotype 1 (HP1) or 2 (HP2). WhatsHap (v2.8) then haplotagged WGS reads to their chromosome of origin and projected phased variants onto biomodal BAMs to estimate haplotype-specific differential methylation. Functional validation included pharmacologic inhibition with the dual BRD4/p300 inhibitor EP31670 in primary CMML specimens, engineered ASXL1mt cell lines, and a genetically engineered Asxl1fl/fl, Nras G12D/+,Vav1-Cre mouse model.

Results: DLK1 (Delta Like Non-Canonical Notch Ligand-1) emerged as one of the most highly upregulated genes in ASXL1mt CMML (log2FC 4.0; FDR=2.8×10−4), accompanied by activation of MEIS1 and HOXA stemness programs.  DNA methylation profiling demonstrated coordinated epigenetic remodeling across the imprinted DLK1-MEG3 locus (14q32), including differential methylation within regulatory CpG islands and the MEG3 differentially methylated region (DMR).  Haplotype-resolved methylation profiling demonstrated recurrent allele-specific loss of methylation at the normally silenced DLK1 allele with reciprocal gain of methylation at the intergenic DMR (IG-DMR), consistent with disruption of genomic imprinting in ASXL1mt vs wild-type CMML samples. These findings were confirmed by digital droplet PCR (SNP rs1802710) demonstrating biallelic expression in ASXL1mt CMML, consistent with disruption of genomic imprinting.

Single-cell chromatin accessibility and ChIP-seq demonstrated preferential activation of enhancer elements around DLK1, MEIS1, and the HOXA locus in ASXL1mt cells. Motif enrichment analyses demonstrated overrepresentation of p300/BRD4 binding within ASXL1mt-specific enhancer regions, while Hi-C confirmed physical interactions between activated enhancers and target promoters. CRISPR-edited ASXL1mt cell lines (U937) demonstrated increased sensitivity to EP31670, while DLK1 knockdown by siRNA augmented in vitro erythroid colony formation and organization.

Pharmacologic p300/BRD4 inhibition suppressed expression of DLK1, MEIS1, HOXA6-10, restored erythroid differentiation, and demonstrated selective activity in ASXL1mt CMML, with minimal effects on normal hematopoiesis. In vivo, EP31670 significantly reduced leukemic burden in a novel genetically engineered Asxl1fl/fl, Nras G12D/+,Vav1-Cre mouse model and prolonged survival in comparison to the vehicle control.

Conclusions: Somatic ASXL1 mutations contribute to aggressive CMML through epigenetic disruption of the imprinted DLK1-MEG3 locus, resulting in loss of DLK1 imprinting, aberrant enhancer activation, and activation of stemness-associated transcriptional programs. These findings highlight disruption of genomic imprinting as a previously unrecognized mechanism of ASXL1-mediated leukemogenesis and provide a strong mechanistic rationale for therapeutic targeting of the BRD4/p300 transcriptional axis in ASXL1mt CMML.

Pankaj Pradeep: No relevant conflicts of interest to declare.